Haydia Haniff


Patients Coping With Insomnia May Benefit from Behavioral Interventions

March 20th 2014

Cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based stress reduction (MBSR) can improve sleep for patients with cancer, but CBT-I continues to be the best nonpharmacologic option

Idelalisib Shows Promising Activity in Heavily Pretreated iNHL

February 26th 2014

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin's lymphoma.

Study Suggests IMRT Improves Survival in Head and Neck Cancer

February 25th 2014

Intensity-modulated radiation therapy (IMRT) improved survival and reduced toxicities compared with conventional radiation treatment in patients with head and neck cancer, according to a recent database analysis.

Dendritic Vaccine Improves Survival in Recurrent Glioblastoma

February 19th 2014

A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments

ALK and ROS1 Lung Cancer Oncogenes May Also Drive Colorectal Cancer

February 7th 2014

Gene rearrangements ALK and ROS1 that are known to drive subsets of lung cancer are also present in colorectal cancer according to a recent study in Molecular Cancer Research.

Brentuximab Vedotin Should Not Be Combined With Bleomycin in First-Line Treatment of Hodgkin Lymphoma

January 8th 2014

Brentuximab vedotin (Adcetris) should not be given with bleomycin as a first-line therapy for patients with advanced-stage Hodgkin lymphoma

Novel Imaging Identifies Changes in Osteosarcoma Earlier in Treatment

December 23rd 2013

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

Predicting Risk of Aggressive Prostate Cancer Through Biomarkers in Blood

December 16th 2013

A new study has shown a possible correlation between men with short-ended chromosomes in the immune cells of their blood and an increased risk of developing aggressive prostate cancer, potentially pointing the way toward an accessible biomarker that could help inform treatment and surveillance decisions.